Cyclerion TherapeuticsCYCN
Market Cap: $7.09M
About: Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Employees: 1
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
13% more funds holding
Funds holding: 15 [Q1] → 17 (+2) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0.71% less ownership
Funds ownership: 39.52% [Q1] → 38.81% (-0.71%) [Q2]
30% less capital invested
Capital invested by funds: $3.43M [Q1] → $2.41M (-$1.02M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for CYCN.